🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against superbug strains of the bacteria, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting over 82 million infections annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in the same week. This medication, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Testing Results and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug cured the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which involves two antibiotics. The trial involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in many developing nations.

Medical professionals treating patients have expressed positive views. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for people and to stop the proliferation of extremely resistant gonorrhoea around the world.